Clinical trials: AIDS
HIV Infections
Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of HIV-1 Chimp Adenovirus Vaccines Expressing Clade C gp140 & CH505TF gp120 Protein Boost in HIV-uninfected Adult.
The purpose of this study is to evaluate the safety and immunogenicity of HIV-1 vaccines based on chimpanzee serotypes of adenovirus expressing clade C gp140 and a CH505TF gp120 protein boost in healthy, HIV- uninfected adult…
- Trial name
- HVTN139 (NCT05182125)
- Testing
- AdC6-HIVgp140, AdC7-HIVgp140, CH505TF gp120
- Where
- 6 sites in South Africa
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- HIV Vaccine Trials Network
HIV Infections
More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents
The purpose of this study was to determine the dosage for oral cabotegravir (CAB) and long-acting cabotegravir (CAB LA) and long-acting rilpiverine (RPV LA) and evaluate the safety, acceptability, tolerability, and…
- Trial name
- MOCHA (NCT03497676)
- Testing
- Oral Cabotegravir (CAB), Oral Rilpivirine (RPV), Long-Acting Injectable Cabotegravir (CAB LA)
- Where
- 19 sites in United States, Botswana and 3 more
- Volunteers
- 168 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)
Demonstrate the safety and efficacy of Tipranavir/Ritonavir versus an active treatment regimen in highly treatment experienced Human Immunodeficiency virus 1(HIV-1) infected patients.
- Trial name
- NCT00054717
- Testing
- Tipranavir, Ritonavir(r), Comparator Protease Inhibitor (CPI)
- Where
- 117 sites in United States, Australia and 2 more
- Volunteers
- 630 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
A Study to Compare the Relative Bioavailability of Two Different Formulations of GSK3640254
This is a first time in human (FTIH), 2-period study, to assess the relative bioavailability of a mesylate salt capsule of GSK3640254, compared to a bis- hydrochloride salt capsule of GSK3640254, in healthy subjects, administered…
- Trial name
- NCT03575962
- Testing
- GSK3640254 bis-hydrochloride salt capsule, GSK3640254 Mesylate Salt Capsule
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Human Immunodeficiency Virus
Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection
This is an early phase research study looking at whether an experimental gene transfer, LVsh5/C46 (also known as Cal-1), is safe and if it can protect the immune system from the effects of HIV without the use of antiretroviral…
- Trial name
- NCT01734850
- Testing
- Busulfan, Cal-1 modified HSPC, Cal-1 modified CD4+ T lymphocytes
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Calimmune, Inc.
HIV Prevention
Pre-Exposure Prophylaxis for Transgender Women in the US and South America
A study to assess the feasibility, acceptability, and preliminary impact of a multi-component strategy to improve pre-exposure prophylaxis (PrEP) uptake and adherence that integrates delivery of biomedical HIV prevention…
- Trial name
- NCT04742491
- Testing
- Immediate Intervention Arm, Deferred Intervention Arm
- Where
- 5 sites in United States, Brazil
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- HIV Prevention Trials Network
HIV
Effects of Eplerenone on Cardiovascular Disease in HIV (MIRACLE HIV Study)
HIV-infected individuals treated with antiretroviral medications are living longer, but have an increased risk of heart disease when compared to non-HIV-infected individuals.
- Trial name
- NCT02740179
- Testing
- Eplerenone, Lifestyle Modification
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Massachusetts General Hospital
Opioid Use Disorder, Infectious Disease
Addressing Risk Through Community Treatment for Infectious Disease and Opioid Use Disorder Now (ACTION) Among Justice-involved Populations
This is a 5-year Hybrid Type 1 Effectiveness-Implementation Randomized Control Trial (RCT) that compares two models of linking and retaining individuals recently released from justice involvement to the continuum of…
- Conditions
- Opioid Use Disorder, Infectious Disease, Risk Reduction Behavior, Substance Use
- Trial name
- ACTION (NCT05286879)
- Testing
- Patient Navigator, Mobile Health Unit
- Where
- 3 sites in United States
- Volunteers
- 601 people
- Sponsor
- Yale University
HIV-1 Infection
Study to Evaluate Effects of Vorinostat and HXTC on Persistent HIV-1 Infection in HIV-Infected Subjects Started on Antiretroviral Therapy (ART)
This is a phase I, single-site, study to evaluate the effects of VOR and HIV-1 Antigen Expanded Specific T Cell Therapy (HXTC) on persistent HIV-1 Infection in HIV-infected individuals suppressed on ART.
- Trial name
- XTRA (NCT03212989)
- Testing
- Vorinostat, HXTC
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of North Carolina, Chapel Hill
Sexually Transmitted Diseases, Gonorrhea
Zenyth: Motivational Interviewing-based Telehealth Intervention for Bacterial Sexually Transmitted Infection Screening
In the United States (US), gay and bisexual men living with human immunodeficiency virus (HIV) bear a heavy burden of bacterial sexually transmitted infections (STIs) such as gonorrhea, chlamydia, and syphilis.
- Conditions
- Sexually Transmitted Diseases, Gonorrhea, Chlamydia, Syphilis
- Trial name
- NCT06100250
- Testing
- Motivational interviewing and specimen self-collection
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Michigan
HIV, Trauma Exposure
Improving the Health of South African Women With Traumatic Stress in HIV Care (C0147)
In this study, the investigators propose to develop Improving AIDS Care after Trauma (ImpACT), an intervention based on theories of stress and coping and evidence-based treatment for traumatic stress.
- Trial name
- ImpACT (NCT02223390)
- Testing
- Improving AIDS Care after Trauma (ImpACT)
- Where
- South Africa
- Volunteers
- 64 people
- Sponsor
- Duke University
HIV Infections
Simplified Model of Linkage and Retention to Care, Using a Mobile Unit and a Same-day Test and Treat Approach Among Excluded Population. (SIMPLIFIED)
Implementation of a model for access and retention of HIV care for vulnerable and excluded population using a mobile screening unit and a strategy of diagnosis and initiation of treatment with Bictegravir (BIC) 50 mg/…
- Trial name
- SIMPLIFIED (NCT05405751)
- Testing
- Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]
- Where
- Spain
- Volunteers
- 101 people
- Sponsor
- Fundacion SEIMC-GESIDA
HIV Infections, Sexually Transmitted Diseases
Evaluation of Many Men, Many Voices, An STD/HIV Prevention Intervention for Black MSM
The purpose of this program evaluation is to determine whether the "Many Men, Many Voices" HIV/STD prevention intervention is effective in reducing HIV sex risk behaviors and increasing HIV testing among African-American men who…
- Trial name
- 3MV (NCT00137631)
- Testing
- Many Men, Many Voices (3MV)
- Where
- United States
- Volunteers
- 341 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention
Diabetes, Insulin Resistance
Dipeptidyl Peptidase-4 Inhibition and Immune Function in HIV
We will test the safety of a new class of anti-diabetes compounds (DPPIV-inhibitors) in people living with HIV. Future trials will examine efficacy for treating diabetes and reducing cardiovascular disease risk in people living…
- Trial name
- DPPIVinHIV (NCT01093651)
- Testing
- Sitagliptin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
AIDS-Related Human Papillomavirus Infection, High Grade Cervical Squamous Intraepithelial Neoplasia
HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV
This randomized phase III trial studies how well human papillomavirus (HPV) vaccine therapy works in reducing high-grade cervical lesions in patients with human immunodeficiency virus (HIV) and HPV.
- Conditions
- AIDS-Related Human Papillomavirus Infection, High Grade Cervical Squamous Intraepithelial Neoplasia, HIV Infection
- Trial name
- COVENANT (NCT03284866)
- Testing
- Laboratory Biomarker Analysis, Recombinant Human Papillomavirus Nonavalent Vaccine, Saline
- Where
- 6 sites in Kenya, Malawi and 3 more
- Volunteers
- 535 people
- Sponsor
- AIDS Malignancy Consortium
Osteoarthritis
Feasibility Study: Effect of Patient Decision Aids for Total Joint Replacement on Surgical Referrals
Ministries of Health consider wait lists for total joint replacement a top priority. Research priorities to manage wait lists indicate the need to establish benchmarks that consider patient preferences.
- Trial name
- NCT00743951
- Testing
- 1 Patient decision aid, 2 Usual care
- Where
- Canada
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- Ottawa Hospital Research Institute
Human Immunodeficiency Virus
Trial to Assess the Continued Safety of and Adherence to a Vaginal Ring Containing Dapivirine in Women
HIV Open-label Prevention Extension (HOPE).
- Trial name
- NCT02858037
- Testing
- Dapivirine Vaginal Ring
- Where
- 17 sites in Malawi, South Africa and 2 more
- Volunteers
- 1,456 people, healthy volunteers welcome
- Sponsor
- International Partnership for Microbicides, Inc.
HIV
Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women
This study seeks to understand the immune cells in the cervical fluid of in the blood and genital tract of HIV-negative healthy female volunteers and to see if these cells can be modified using a combined anti-viral and…
- Trial name
- MIP (NCT02333045)
- Testing
- Truvada qd, Maraviroc 300 qd
- Where
- 2 sites in United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Emory University
HIV
A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)
A study to evaluate the safety, tolerability and efficacy of once daily Raltegravir compared to twice daily raltegravir when each is given in combination with TRUVADA™ in treatment-naïve human immunodeficiency virus…
- Trial name
- NCT00745823
- Testing
- Comparator: Raltegravir 400 mg b.i.d., Experimental: Raltegravir 800 mg q.d., TRUVADA™
- Volunteers
- 775 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2)
The objective of this study is to demonstrate the safety and efficacy of tipranavir/ritonavir versus an active control arm in highly treatment experienced Human immunodeficiency virus-1 infected patients.
- Trial name
- NCT00144170
- Testing
- Tipranavir (with low dose ritonavir), Comparator protease inhibitor(CPI)/low dose ritonavir(r)
- Where
- 174 sites in Argentina, Austria and 15 more
- Volunteers
- 882 people
- Sponsor
- Boehringer Ingelheim